Journal: Scientific reports
This study analyzed 4,718 patients with FIGO stage IIB cervical cancer from the SEER database (1988–2015) to compare survival outcomes between surgery and chemoradiotherapy.
After propensity score matching, surgery was associated with significantly improved 5-year overall survival (68.0% vs. 59.9%) and cancer-specific survival (70.4% vs. 62.9%) compared to chemoradiotherapy alone.
Multivariate analysis confirmed treatment modality as an independent prognostic factor.
Subgroup analyses showed:
- Surgery benefited patients with ≤4 cm squamous-cell carcinoma and >4 cm non-squamous-cell carcinoma
- No survival advantage for surgery in >4 cm squamous-cell or ≤4 cm non-squamous-cell tumors
The findings suggest a surgery-based approach may improve survival in FIGO stage IIB cervical cancer, with effects influenced by tumor size and histology.